A phase 2 dose-optimization study of lonafarnib with ritonavir for the treatment of chronic delta hepatitis—end of treatment results from the LOWR HDV-2 study

YURTAYDIN S. C., İDİLMAN R., KESKİN O., KALKAN Ç., KARAKAYA M. F., ÇALIŞKAN KARTAL A., ...More

International Liver Congress 2017, 19 - 23 April 2017, vol.66, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 66
  • Hacettepe University Affiliated: Yes